A Review of Direct Oral Anticoagulants in Patients With Stage 5 or End-Stage Kidney Disease
CONCLUSIONS: If OACs for stroke prevention with AF are deemed necessary, apixaban or rivaroxaban can be considered. DOACs cannot currently be recommended over warfarin in patients with CKD-5 or ESKD and VTE.PMID:34459281 | DOI:10.1177/10600280211040093
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Jessica A Starr Nathan A Pinner Melanie Mannis Mary Katherine Stuart Source Type: research
More News: Atrial Fibrillation | Bleeding | Chronic Kidney Disease | Coumadin | Databases & Libraries | Drugs & Pharmacology | Pradaxa | Pulmonary Thromboembolism | Stroke | Study | Thrombosis | Urology & Nephrology | Warfarin